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Abstract Autophagy is a cellular self-catabolic process
in which cytoplasmic constituents are sequestered in dou-
ble membrane vesicles that fuse with lysosomes where they
are degraded. As this catabolic activity generates energy,
autophagy is often induced under nutrient limiting condi-
tions providing a mechanism to maintain cell viability and
may be exploited by cancer cells for survival under meta-
bolic stress. However, progressive autophagy can be
cytotoxic and autophagy can under certain settings sub-
stitute for apoptosis in induction of cell death. Moreover,
loss of autophagy is correlated with tumorigenesis and
several inducers of autophagy are tumor-suppressor genes.
Thus, the relation of autophagy to cancer development is
complex and depends on the genetic composition of the
cell as well as on the extra-cellular stresses a cell is
exposed to. In this review we describe the intricate nature
of autophagy and its regulators, particularly those that have
been linked to cancer. We discuss the multifaceted relation
of autophagy to tumorigenesis and highlight studies sup-
porting a role for autophagy in both tumor-suppression and
tumor-progression. Finally, various autophagy-targeting
therapeutic strategies for cancer treatment are presented.
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Introduction
Autophagy is a self-digestive process wherein bulk
cytoplasmic components and intra-cellular organelles are
sequestered in double membrane vesicles named auto-
phagosomes. Upon maturation, autophagosomes fuse with
lysosomes where their contents are degraded by the lyso-
somal proteases. The process of autophagy was initially
described as a mechanism of cell survival under nutrient
limiting conditions. Specifically, the autophagic catabolic
activity enables cells to restore sufficient energy levels in
the absence of nutrients and consequently promotes
viability [1]. This feature of autophagy is of particular
importance during developmental processes, as it is sug-
gested to maintain normal metabolism by providing an
alternative cellular source for energy. Incidentally, defi-
ciency of Beclin 1 is embryonic lethal and Atg5 or Atg7 null
mice fail to survive the neonatal starvation period and die
perinatally [2, 3]. In addition, it has been established that
basal autophagy is also essential for keeping cellular
homeostasis by mediating the normal turnover of organelles
and long-lived proteins. Disruption of this homeostasis can
have severe effects. For example, deletion of Atg5 or Atg7
results in accumulation of polyubiquitinated proteins in the
nervous system leading to neurodegeneration [4, 5]. A cyto-
protective role of autophagy is also described during the
immune response and includes defense against pathogens
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and T cell repertoire shaping [6, 7]. Paradoxically, many
lines of evidence also describe a role for autophagy in
antagonizing cell survival and promoting cell death, clas-
sified as autophagic, or type II, cell death. This discrepancy
is partially resolved by the presumption that extensive
activation of autophagy might lead to the disintegration of
major cellular systems, such that ‘‘the point of no return’’ is
crossed and recovery of the cell is unattainable. Other
specific cellular settings, such as the integrity of other cell
death systems, also influence the balance between the dual
functions of autophagy.
The course of tumorigenesis involves many genetic
alterations that collectively lead to cellular transformation
and tumor growth. Intensive studies over the years delin-
eated the contribution of loss of apoptotic (also named type
I) cell death, responses to tumor formation [8]. Accordingly,
numerous key regulators of apoptosis were described as
tumor-suppressor genes and their cellular function was
extensively studied. With the identification of autophagy as
an alternative cell death program, its contribution to
tumorigenesis was evaluated as well. Remarkably, the
process of autophagy was revealed to be critical in certain
scenarios of tumor formation. However, the link between
autophagy and cancer appears to be multifaceted. Loss of
autophagic responses is correlated with cancer development
and furthermore, various inducers of autophagy including
Beclin 1, p53, DAPk, p19ARF, TSC, LKB, and PTEN have
been described as tumor-suppressors. Therefore, loss of
autophagy might contribute to tumor-progression due to a
failure to eliminate damaged cells through type II cell death,
as in the case of loss of apoptotic responses. In addition, the
cyto-protective features of autophagy can also contribute
indirectly to its tumor-suppressive function such that loss of
the autophagic-homeostasis maintenance might expose
cells to various defects such as accumulation of damaged
mitochondria. Damaged mitochondria produce high levels
of free radicals that often cause damage to DNA resulting in
genetic alterations that may promote tumor development.
However, autophagy bears a different facet as well that
correlates with promotion of cell survival under stress. As a
corollary, autophagy might be advantageous to tumor
development and its inhibition could therefore be required
to block tumorigenesis.
In conclusion, autophagy is an intricate process with
multiple biological aspects. Great effort is invested in
deciphering its mechanistic features and their relevance to
physiological processes, particularly to tumorigenesis. In
contrast to the unambiguous role of the apoptotic network
in tumor-suppression, the relation between autophagy and
cancer is complex. This review will discuss the link
between autophagy and cancer and will explore different
autophagy-inducing drugs that are being used as anti-can-
cer therapy in the clinic.
The molecular mechanism of autophagy
Deciphering the molecular mechanism of autophagy began
in 1993 with the identification of the autophagy-related
genes (Atg) in the yeast Saccharomyces cerevisiae [9].
Most of the Atg genes are conserved from yeast to humans
and many orthologs of these genes have been identified in
mammalian cells. The first steps in the formation of the
autophagic vacuole are mediated by the class III phos-
phatidylinositol 3-kinase (PI3KC3), the ortholog of Vps34,
the sole PI3K in yeast [10]. Among the key players in the
autophagic machinery are those that form a complex with
Vps34 and regulate its activity, such as Beclin 1 (the
mammalian ortholog of Atg6) and the myristylated serine
kinase Vps15/p150 [11]. UVRAG and Bif-1 are positive
regulators of the interaction between Beclin 1 and Vps34,
and thus promote Vps34 activation [12, 13]. Vps34 also
binds Atg14 that directs the Vps34-complex to the orga-
nizing centers of autophagosome formation, known as the
pre-autophagosomal structures (PAS) [14]. The mamma-
lian ortholog of Atg14 has been recently identified [15].
Although the source of the autophagosomal membrane is
still unidentified, the localization of Beclin 1 and Vps34 to
the endoplasmic reticulum and trans-golgi network [16]
suggests these sites as candidates for the autophagosome
origin. The nucleation step of autophagosome biogenesis
requires activation of Vps34 that produces phosphatidyl-
inositol 3-phosphate (PI3P). PI3P presumably acts by
recruiting proteins that contain PI3P-binding FYVE and
PX domains, which are predicted to control membrane
formation and elongation. An example is Atg18 that in
complex with Atg2 is recruited to the PAS via phospho-
lipids binding [17, 18].
The serine/threonine kinase Atg1 is essential for the
induction of autophagy. In yeast, Atg1 activation requires its
interaction with Atg13. TOR negatively regulates this step
by phosphorylating Atg13 which reduces its affinity for
Atg1 binding [19, 20]. Still, the specific function of Atg1 or
of its mammalian ortholog, ULK1 (UNC-51-like kinase 1),
is undefined, as well as the mechanism which couples its
function to the activation of the Beclin 1/Vps34 complex.
Elongation of the autophagic vacuole membrane is
mediated by two ubiquitin-like pathways. Atg12, a ubiq-
uitin-like protein, is covalently conjugated to Atg5 by the
action of the E1- and E2-like proteins Atg7 and Atg10,
respectively [21–24]; Atg7 and Atg3 similarly act as
E1- and E2-enzymes in the second ubiqutin-like pathway
in which Atg8 (mammalian LC3) is lipidated by conjuga-
tion to phosphatidylethanolamine (PE) [25]. The Atg12–
Atg5 dimer is recruited to the outer autophagosomal
membrane, presumably via interaction with Atg16 [26, 27].
In accord, the site of LC3 lipidation is determined by the
membrane localization of Atg16 [28]. Recently, the
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Atg12–Atg5 dimer was shown to have E3-like activity for
Atg8 conjugation to PE [29]. This critical step in auto-
phagosome expansion is mediated by the formation of an
amide bond between the amino group of PE and the car-
boxyl-terminal glycine residue of Atg8, which is exposed
following cleavage of the C-terminus of Atg8 by the cys-
teine protease Atg4 [25, 30]. Lipidation of Atg8, which
occurs only under stimulation of autophagy, converts Atg8
from its soluble cytoplasmic form (LC3-I) to the mem-
brane-bound, autophagosome-associated, form (LC3-II).
The recruitment of Atg8 to autophagosomes is rate limiting
in the process of membrane expansion. Atg8-PE mediates
membrane tethering and hemifusion [31] and the amount of
Atg8 at the PAS determines the size of the autophagosome
[32]. Once the autophagosome is fully expanded, Atg8 is
deconjugated from PE via the action of Atg4 and is
released back to the cytosol [30]. Likewise, the Atg12–
Atg5–Atg16 complex dissociates from the autophagosome
membrane upon maturation.
Upon maturation, the autophagosome fuses with
organelles of the endocytic compartment (early or late
endosomes and lysosomes) to form the autolysosome. In
yeast, this process was shown to require Ypt7p (the yeast
homologue of Rab7) [33], Vam3p (a syntaxin homologue)
[34], Sec18p (yeast homologue of N-ethylmaleimide sen-
sitive factor, NSF), and Vti1p (a SNARE protein) [35]. A
similar role for Rab7 and Vti1p was demonstrated in
mammalian cells [36–38]. Interestingly, UVRAG, which
facilitates Vps34 activation in the early steps of auto-
phagosome formation, has a second role in later stages of
autophagy wherein it regulates autophagosome maturation
in a Beclin 1-independent manner. UVRAG facilitates the
recruitment of the class C vacuolar protein sorting (C-Vps)
complex to autophagosomes. The C-Vps complex has been
extensively studied in fusion events between the endosome
and vacuole in yeast. The interaction between UVRAG and
the C-Vps complex stimulates Rab7–GTPase activity and
results in autophagosome to lysosome fusion [39]. Fusion
takes place in the perinuclear region which is enriched in
lysosomes. For this to occur, autophagosomes must move
from the cytosol towards the nucleus. The movement of
autophagosomes occurs on microtubules [40, 41] and is
mediated by the motor protein dynein [42]. Finally, the
engulfed cytoplasmic proteins and organelles within the
autolysosome are degraded by lysosomal proteins.
Tumor-suppressor genes and oncogenes
that regulate/execute autophagy
One of the strong indications which link autophagy to
cancer is the finding that some of the autophagic genes, or
the genes which regulate the autophagic process, function
as tumor-suppressors or oncogenes. Below we describe a
few major examples.
Beclin 1 and its regulators
Beclin 1 was originally identified as a novel Bcl-2-inter-
acting, coiled-coil protein, which has structural similarity
to yeast Atg6. The autophagic function of Beclin 1 is
evolutionary conserved and has been demonstrated in
various species including yeast [43], dictyostelium [44],
plants [45], C. elegans [46], mice [2, 47], and humans [48,
49]. The identification of Beclin 1 as a tumor-suppressor
gene in 1999 established the first connection between
autophagy and cancer [48]. The Beclin 1 locus (17q21) is
frequently subjected to monoallelic deletions in human
breast, ovarian, and prostate cancer as well as in brain
tumors, signifying Beclin 1 as a haplo-insufficient tumor-
suppressor gene in humans [48, 50, 51]. Studies in mice
confirmed the findings in human tumors. Heterozygous
gene disruption in mice resulted in the development of
spontaneous breast and lung tumors, lymphoma, and
hepatocellular carcinoma [2, 47]. Incidentally, Beclin 1
gene transfer induced autophagy and inhibited the tumor-
igenesis of human breast carcinoma cells in clonigenicity
assays and in mouse xenograft models [48]. These findings
suggested that the tumor-suppressive functions of Beclin 1
are associated with its positive regulation of autophagy. As
detailed above, Beclin 1 acts as a platform for the
recruitment and activation of the Vps34 complex, which is
essential for the initiation of the early stages of autophagy
(Fig. 1). An evolutionary conserved region of human
Beclin 1, spanning from amino acids 244–337, is respon-
sible for Vps34 binding and activation, and is thus required
for the induction of autophagy. Remarkably, this region is
also necessary for the inhibition of tumorigenicity in mice
[49], supportive of the notion that the tumor-suppressive
and autophagic functions of Beclin 1 are interrelated.
Several regulators of Beclin 1 have been implicated in
tumorigenesis. UVRAG, a Beclin 1-binding protein, is a
tumor-suppressor candidate which maps to chromosome
11q13. Disruption of this locus is frequently associated with
development of different human malignancies, including
breast and colon cancers [52]. Monoallelic deletions or
mutations in UVRAG have been reported in numerous
human malignancies [53–55]. UVRAG and Beclin 1
directly interact via their coiled-coil domains and this
interaction is suggested to promote Vps34 binding to and
activation by Beclin 1 [12, 56]. The expression of UVRAG
was shown to be required for Beclin 1-induced autophagy in
human colon and breast cancer cells. Furthermore, UVRAG
suppressed cell proliferation and tumor formation in vivo
[12]. Bif-1 (also known as endophilin B1) is another Beclin
1-binding protein that suppresses tumorigenesis. Bif-1
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interacts with Beclin 1 via UVRAG and promotes Vps34
activation and autophagosome formation. Bif-1 knock-out
mice develop normally, unlike Beclin 1 null mice which are
embryonic lethal, but demonstrate a high rate of tumor
incidence. About 89.7% of Bif-1-/- mice developed
spontaneous tumors at 12 months of age, compared to
14.3% of wild-type mice [13]. Moreover, reduced Bif-1
expression was observed in gastric carcinomas [57], inva-
sive urinary bladder and gallbladder cancers [58], and a
homozygous deletion of the Bif-1 gene was identified in
mantle cell lymphomas [59]. Taken together, these findings
suggest that two of the positive regulators of Beclin 1,
UVRAG and Bif-1, function as potential tumor-suppressor
genes. Bcl-2, an oncogenic negative regulator of Beclin 1, is
discussed in the section below.
Bcl-2
The Bcl-2 family includes proteins containing at least one
Bcl-2 homology (BH) region. In mammals, the Bcl-2 family
is subdivided into anti-apoptotic members (such as Bcl-2
and Bcl-XL), which contain four BH domains, pro-apoptotic
members (such as Bax and Bak), which contain three BH
domains, and the typically pro-apoptotic BH3-only mem-
bers. The Bcl-2 gene was initially found to be disrupted in
most cases of follicular lymphomas carrying the t(14;18)
chromosomal translocation [60]. Transgenic mice carrying
a Bcl-2 immunoglobulin minigene fusion, that recapitulates
the t(14;18) translocation, were found to develop follicular
hyperplasia and lymphoma [61, 62]. Interestingly, unlike
other previously characterized oncogenes, what accounted
for Bcl-2’s oncogenic properties was inhibition of cell death
rather than acceleration of proliferation.
The anti-cell death function of Bcl-2 was for years
attributed solely to the inhibition of apoptosis. However, the
identification of Beclin 1 as a Bcl-2 binding protein [48] was
the first in the line of studies connecting Bcl-2 to a different
program of cell death, namely autophagy. The first sugges-
tion that Bcl-2 is involved in non-apoptotic cell death came
with the finding that downregulation of Bcl-2 results in
increased caspase-independent cell death in human leukemic
HL60 cell line [63]. An anti-autophagic role of Bcl-2 was
demonstrated in vivo where transgenic cardiac-expression of
Bcl-2 in mice inhibited starvation-induced autophagy in the
cardiac muscle [64]. Additionally, targeted silencing of Bcl-2
expression in human breast cancer cells with RNA-interfer-
ence has been shown to promote autophagic cell death and
thus presents a therapeutic potential [65].
The mechanism by which Bcl-2 inhibits autophagy is
reliant on its interaction with Beclin 1. Beclin 1 contains a
functional BH3 domain through which it binds to the BH3-
binding groove in Bcl-2/Bcl-XL [66–68]. In contrast to wild-
type Bcl-2, mutants that are defective in Beclin 1 binding
failed to inhibit autophagy following nutrient starvation in
Beclin 1 expressing human breast carcinoma cells [64]. The
binding of Bcl-2 to Beclin 1 inhibits autophagy by nega-
tively regulating the autophagy-promoting Beclin 1–Vps34
complex. For example, binding of Bcl-2 to Beclin 1 in
autophagy-competent colon carcinoma cells decreased the
association of Beclin 1 with Vps34 and consequently
inhibited autophagy [64]. Recent findings further resolved
the manner by which Bcl-2 inhibits the formation of the
Beclin 1-Vps34 complex. Beclin 1 forms a dimer that is
stabilized by Bcl-2. Interaction with UVRAG disrupts the
dimerization interface of Beclin 1 and induces its mono-
merization. Bcl-2 and Bcl-XL reduce the binding affinity of
UVRAG to Beclin 1 and thereby prevent its monomerization
[56]. As UVRAG and Bcl-2 are known to have opposing
functions on Beclin 1-induced Vps34 activation, it is plau-
sible that monomerization of Beclin 1 is required for Vps34
binding and activation. The association of Bcl-2 with Beclin
1 is regulated in a stress-dependent manner. Endogenous
Bcl-2 is found constitutively bound to Beclin 1 in HeLa
cells. Elevated levels of interaction are observed under
nutrient-rich (autophagy inhibitory) conditions, whereas
following nutrient withdrawal (autophagy stimulatory con-
ditions) the interaction is significantly reduced to minimal
levels, correlating with activation of autophagy [64].
Different mechanisms have been proposed to mediate
the dissociation of Beclin 1 from Bcl-2. One model depicts
that other BH3-containing proteins will competitively
Fig. 1 Signaling pathways that regulate autophagy. Positive regula-
tors of autophagy are illustrated in green while negative regulators are
illustrated in red. The Beclin 1-Vps34 complex is required for
induction of autophagy and its activity is negatively regulated by
binding of Beclin 1 to Bcl-2 and by JNK, which releases Bcl-2
inhibition through phosphorylation. Other negative regulators of
autophagy include growth factor receptors (GFR), which lead to
activation of mTOR through AKT and the Ras pathway. However, erk
has also been demonstrated to act under certain settings as an inducer
of autophagy. p53 has a dual function and can either induce or inhibit
the induction of autophagy
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displace the Beclin 1 BH3 domain from Bcl-2/Bcl-XL. This
model is supported by evidence showing that BH3-mi-
metics and BH3-only proteins disrupt the association of
Beclin 1 with Bcl-2/Bcl-XL and induce autophagy [66, 69].
Interestingly, a viral form of Bcl-2, such as that encoded by
the tumorigenic murine c-herpesvirus 68, binds Beclin 1
with a much higher affinity than cellular Bcl-2. This high
affinity binding renders the viral Bcl-2 resistant to com-
petition by BH3-only proteins and to displacement from
Beclin 1 [70]. Therefore, inhibition of Beclin 1 by consti-
tutive binding to viral Bcl-2 prevents the induction of
autophagy and is a plausible contributor to the tumor-
promoting properties of such viruses.
A second mechanism for the dissociation of Beclin 1
from Bcl-2 was suggested to be dependent on Bcl-2
phosphorylation. Bcl-2 can undergo phosphorylation by
c-Jun N-terminal Kinase (JNK) on residues in the non-
structured loop (T69, S70, and S87). Recently, this phos-
phorylation event was shown to regulate Beclin 1 binding
to Bcl-2 and was linked to autophagy [71]. Following
nutrient starvation, JNK was readily activated and led to
the phosphorylation of the non-structured loop of Bcl-2
(T69, S70, and S87). A non-phosphorylatable Bcl-2
mutant, in which these residues were substituted with
alanines, did not dissociate from Beclin 1 under starvation
and inhibited the induction of autophagy. Loss of active
JNK, either by pharmacological inhibition or by knock-out,
had a similar inhibitory effect on Beclin 1 binding and
autophagy. Conversely, expression of a constitutively
active JNK was sufficient for the induction of Bcl-2
phosphorylation, release from Beclin 1, and stimulation of
autophagy [71]. Thus, JNK positively regulates autophagy
through direct phosphorylation of Bcl-2 and this leads to
the release of the inhibitory lock on Beclin 1. Interestingly,
only the ER-localized pool of Bcl-2 is subjected to regu-
lation by these two mechanisms [66, 71], suggesting that
spatial regulation is critical for the initiation of autophagy.
In conclusion, the inhibitory effect of Bcl-2 on autoph-
agy suggests novel approaches for anti-cancer drug design.
Targeting Bcl-2 binding to Beclin 1 will stabilize the
monomeric, UVRAG-bound form which actively promotes
autophagy. This can be achieved by strategies including
competitive displacement of the BH3-domain of Beclin 1
from Bcl-2 by BH3-mimetics, or by promoting JNK acti-
vation. Alternatively, agents that disrupt the dimerization
interface of Beclin 1 or stabilize its monomeric form might
favor Vps34 binding and activation of autophagy.
mTOR and the signaling pathways which regulate
its activity
One of the major regulators of autophagy is the target of
rapamycin (TOR) which sends the main inhibitory signals
to autophagy when nutrients and energy are prevalent.
TOR, a conserved serine/threonine kinase, acts as a sensor
of growth factors, nutrients, and energy-availability and its
activation is associated with protein synthesis, cell growth,
and with the inhibition of autophagy [72, 73]. TOR exists
in two distinct complexes, TORC1 and TORC2 that are
conserved from yeasts to mammals. Mammalian TORC1
(mTORC1) contains GbL and raptor while mTORC2
contains GbL, rictor, SIN1, and protor [74]. However, only
TORC1 is sensitive to inhibition by rapamycin [74]. The
two central substrates of mTORC1 are 4E-BP1 and
p70S6K which link mTOR to the control of protein syn-
thesis. Phosphorylation of 4E-BP1 leads to its dissociation
from the RNA cap-binding protein eIF4E. This allows the
assembly of the eIF4F complex that enhances cap-depen-
dent mRNA translation [75]. Phopshorylation and
activation of p70S6K leads to increased translation of TOP
mRNAs that encode components of the translational
apparatus such as ribosomal proteins and elongation factors
[76, 77]. An example for a p70S6K target involved in
translation is eEF-2 kinase. eEF-2 kinase phosphorylates
eEF-2 and this blocks the elongation step of translation.
Phosphorylation of eEF-2 kinase by p70S6K inhibits its
activity, therefore preventing eEF-2 phosphorylation. This
removes the block on eEF-2 and promotes protein trans-
lation [78].
mTOR activity is directly stimulated by Rheb, a small
GTP-binding protein which binds to and activates mTOR
in its GTP-bound form [79]. The tuberous sclerosis com-
plex (TSC)1/TSC2 heterodimer acts as the GTPase-
activating protein for Rheb, thus negatively regulating
Rheb and mTOR activity [80]. The TSC1/TSC2 complex
which integrates input from numerous upstream signals
plays a central role in the control of mTOR signaling
(Fig. 1). Phosphorylation by AKT, ERK, or RSK, all of
which are stimulated by growth factors, inactivates the
TSC1/TSC2 complex and allows Rheb activation of mTOR
[79, 81, 82]. In contrast, phosphorylation by AMP-acti-
vated kinase (AMPK), which is activated under nutrient
and energy depletion by high AMP/ATP ratios, activates
the TSC1/TSC2 complex and leads to inactivation of
mTOR [83]. Notably, TSC1 and TSC2 act as tumor-sup-
pressors and mutations in these genes lead to development
of the tuberous sclerosis syndrome, a pathogenesis char-
acterized by the formation of benign tumors in various
organs [84].
The inhibitory role of TOR in regulation of autophagy is
conserved from yeast to humans. In yeast, under conditions
that block TOR activation such as nutrient deprivation or
rapamycin treatment, dephosphorylated Atg13 binds Atg1
and autophagy is induced. The precise manner by which
mTOR inhibits autophagy in mammalian cells needs to be
further elucidated. S6K has also been suggested to be
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involved in regulation of autophagy by TOR through
feedback inhibition of class I PI3K-dependent insulin sig-
naling pathway [85, 86]. As was described above, class I
PI3K signaling activates mTOR and thus inhibits autoph-
agy. Notably, class I PI3K, as well as its downstream
targets AKT, ERK, and RSK1, all of which activate
mTOR, are all oncogenes associated with aberrant uncon-
trolled cell growth [87]. On the other hand, PTEN, a
protein and phospholipid phosphatase that negatively reg-
ulates PI3K signaling, is a known tumor-suppressor that is
subject to deletions and mutations in numerous malignan-
cies [88]. In summary, numerous signaling molecules that
control mTOR activation have been implicated in tumor
development. Whilst each of these molecules has multiple
cellular targets, it is plausible that modulation of autophagy
through mTOR regulation contributes to their oncogenic or
tumor-suppressive properties. Implications of mTOR-tar-
geted cancer therapy are further discussed below.
p53
Nearly 50% of all human malignancies harbor deletions or
mutations of p53. As a pivotal regulator of the cell cycle
checkpoints and an inducer of cell cycle arrest, senescence
and apoptosis, p53 is the best-characterized tumor-sup-
pressor to date. Recently, autophagy was added to the list
of p53-regulated events. Interestingly, different reports
describe p53 as either a positive or a negative regulator of
autophagy. This section will summarize the main findings
thus far and allude to the paradox of p53’s opposing roles
in autophagy.
A role for p53 as a positive regulator of autophagy was
described upon exposure of cells to genotoxic stress.
Activation of p53 following treatment with the DNA-
damaging agent etoposide led to inhibition of mTOR and
resulted in the induction of autophagy. mTOR inhibition
was dependent on AMPK activation by p53 and was
mediated by TSC1 and TSC2 since their deletion abrogated
p53’s ability to inhibit mTOR [89]. In addition to DNA-
damage, oncogenic stress as recapitulated by overexpres-
sion of p19ARF also provided a trigger for p53-induced
autophagy [90]. Interestingly, p53-induced autophagy is
mediated not only by the inhibition of mTOR but also
through p53’s transcriptional activity. Under genotoxic
stress, p53 was shown to upregulate the transcription of
DRAM (damage-regulated modulator of autophagy) [91].
DRAM, a 238 a.a. protein, highly conserved in higher
eukaryotes, is localized to the lysosomal membrane.
Knock-down of DRAM expression promoted survival after
exposure to DNA-damage and DRAM was shown to be
required for p53-induced autophagy and cell death. Knock-
down of Atg5 expression inhibited this effect indicating
that the DRAM-mediated p53-induced cell death involves
the autophagic machinery. Interestingly, DRAM was found
to be down-regulated in squamous cancers suggesting a
role for DRAM as a tumor-suppressor gene [91].
In contrast to the abovementioned, loss of p53 function
(by pharmacological inhibition or deletion) can trigger the
onset of autophagy as well [92]. The lack of p53 expression
alone was sufficient to induce high levels of basal
autophagy. This enhancement of basal autophagy could
not, however, be further augmented by different stimula-
tors of autophagy such as nutrient starvation, rapamycin or
ER-stress [93]. Interestingly, cytoplasmic localization of
p53 mediates its inhibitory function towards autophagy.
Restoration of p53 expression in p53-/- cells with mutants
that are restricted to the cytoplasm (lacking the nuclear
import sequence) effectively inhibited the autophagic
response initiated by the loss of p53. In contrast, nuclear
mutants of p53 (lacking the nuclear export sequence) failed
to block autophagy. Therefore, regulation of autophagy by
p53 is tightly regulated at the level of p53 localization with
a nuclear localization favoring induction of autophagy
while a cytoplasmic localization serves to hinder basal
autophagy. Remarkably, several inducers of autophagy
(starvation, rapamycin and ER-stress) were demonstrated
to induce MDM2-dependent degradation of p53 [92]. Thus,
p53 not only regulates autophagy but is also regulated by it
at the level of protein stability.
It is a well-established notion that inactivation of p53 is
advantageous for cancer cell survival. How then can the
enigma of the dual role of p53 in autophagy regulation be
explained? A suggestion might be that it is the particular
cellular environment and specific stress that a cell is
exposed to, or the precise stage in tumor formation, that
dictates the final outcome. In early stages of tumorigenesis,
genotoxic insults that activate autophagy through p53
could possibly be part of the ‘‘gate-keeping’’ function of
p53. In such scenarios, autophagy may act as a cell death
mechanism aimed at eliminating defective cells. However,
once a tumor is formed, inactivation of p53 by deletion or
mutation, or degradation of p53 following nutrient depri-
vation inside the tumor mass, might activate autophagy as
an energy providing mechanism. In this case, autophagy
might provide a survival advantage by continuously sup-
plying energy to the tumor cells. Indeed, p53 null cells
were shown to maintain ATP levels even when nutrients
were withdrawn. Furthermore, cell viability under those
conditions was shown to require the autophagic system
[92].
Death associated protein kinase (DAPk)
Death associated protein kinase (DAPk), a calcium-cal-
modulin activated serine/threonine kinase, is a tumor-
suppressor whose expression is lost in numerous human
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malignancies including B and T cell lymphomas, breast
cancer, lung carcinoma, head and neck cancer, gastric
cancer, cervical cancer, and prostate cancer [94, 95]. Loss
of DAPk expression is principally due to epigenetic
silencing by promoter hyper-methylation. In addition, a
germline mutation in DAPk was found in cases of familial
chronic lymphocytic leukemia (CLL), where a single
nucleotide exchange increases the binding affinity of the
HOXB7 transcription factor to the DAPk promoter, leading
to silencing of the gene and predisposition to CLL [96].
Notably, loss of expression of DAPk is now being used as a
diagnostic tool for cancer detection in tumor samples.
DAPk functions at several stages of tumor development. At
the early stages of tumorigenesis, DAPk blocks oncogenic
transformation by activating a p53/p19ARF-dependent
apoptotic checkpoint [97]. DAPk activation was shown in
this context to increase p53 expression and transcriptional
activity, leading to caspase-dependent cell death. Another
major step in tumorigenesis that is inhibited by DAPk is
tumor metastasis. Injection to mice of highly metastatic
lung carcinoma cells, in which the DAPk gene was not
expressed, resulted in excessive formation of metastases.
However, reintroduction of DAPk in physiological
expression levels in these cells significantly reduced
metastases formation in the injected mice. This was by and
large due to the sensitization of the cells to various death
stimuli and to the induction of anoikis (cell death induced
by detachment from the matrix) [98]. In fact, adhesion
signaling and migratory cues are tightly regulated by
DAPk. Activation of integrins and integrin-mediated sur-
vival signaling are suppressed by DAPk, which promotes
p53-dependent apoptosis upon loss of cell adhesion [99].
Moreover, DAPk blocks tumor cell migration and invasion,
both being critical steps in the process of metastasis. By
interfering with the association of talin with the beta-
integrin tail, DAPk prevents CDC42 activation and thus
inhibits cell polarization and migration. Interestingly, this
inhibitory effect on cell migration and invasion is inde-
pendent of the apoptotic function of DAPk and is observed
even in p53-deficient cells. Thus, the multifaceted nature of
DAPk activity contributes to its competent tumor-sup-
pressive function.
DAPk was originally identified as a gene involved in
IFN-c-induced cell death in HeLa cervical cancer cells
[100]. Interestingly, IFN-c induced caspase-independent
cell death in these cells that was reminiscent of autophagy.
Moreover, overexpression of DAPk was by itself sufficient
to induce autophagosome accumulation [101]. Interest-
ingly, DAPk was shown to also act as an inducer of
caspase-dependent apoptotic cell death in different cellular
scenarios [102] as well as of programmed necrosis through
the phosphorylation of PKD and activation of JNK [103].
The involvement of DAPk in the regulation of different
programs of cell death raised the intriguing possibility that
DAPk functions at the cross road of necrosis, apoptosis and
autophagy, switching between or integrating these path-
ways under specific settings. In this regard, it was recently
shown that DAPk is activated under ER-stress leading to
both apoptotic and autophagic death in the same cell [104].
The fact that DAPk is an integrator of various stimuli that
induces distinct cell fates suggests that more than a single
mechanism would account for its mode of action. A clue to
one possible mechanism by which DAPk induces autoph-
agy arose from a screen of peptide libraries aimed at
isolating novel proteins which bind to the kinase domain of
DAPk [105]. This screen identified the interaction between
DAPk and MAP1B, a protein mainly implicated in neu-
ronal differentiation and neurite growth. Interestingly,
MAP1B interacts with high affinity with LC3 and phos-
phorylated MAP1B associates with autophagosomes [106].
Although, as to date, MAP1B was not recognized as a
substrate of DAPk, their interaction was suggested to reg-
ulate membrane blebbing during a caspase-independent
death process [105]. Further studies are required to delin-
eate the downstream signals through which DAPk induces
autophagy and to decipher the regulation of the switch
between apoptosis and autophagy.
Further substantiation of DAPk as a significant regulator
of autophagy came from studies in C. elegans which
investigated autophagy at the multicellular organism level.
In C. elegans, starvation induces autophagy that, depend-
ing on its level, has opposing roles promoting either
survival or death of the organism. During starvation, the
muscarinic acetylcholine pathway plays a central role in
the induction of autophagy in the pharyngeal muscle whose
activity is critical for the recovery from starvation.
Remarkably, DAPk was identified as a mediator of star-
vation-induced autophagy in C. elegans [107]. Over-
activation of the muscarinic signaling pathway causes
excessive autophagy in the pharyngeal muscle and leads to
death of the organism, presumably by malfunction of the
muscle. Mutation in DAPk or knock-down of its expression
partially rescued the phenotype of muscarinic signaling
over-activation by reducing autophagy and promoting
survival of the animal. Whether DAPk acts downstream or
in parallel to muscarinic signaling remains to be elucidated
in future studies.
The paradox of autophagy and its implications
in suppressing/activating tumor development
Studying autophagy presents a paradox; it is a homeostatic
cyto-protective mechanism that under metabolic stress
promotes survival but can nevertheless, under certain set-
tings, act as a program of caspase-independent cell death
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(Fig. 2). This section will focus on the ambiguity of the
autophagic function and its relation to other cell death
programs, and will consider its implications in suppressing/
activating tumor development.
The cross talk between autophagy and apoptosis
Many lines of evidence now indicate that common death
stimuli, previously attributed to the induction of apoptosis
solely, trigger autophagy as well. Examples of these
include etoposide, an inducer of p53-dependent apoptosis,
that was shown to induce autophagy in mouse embryonic
fibroblasts in a p53-dependent manner [89]; Ligation of the
TRAIL receptor-2 by human scFv antibody triggered
autophagic cell death in both TRAIL-sensitive and TRAIL-
resistant cancer cells [108]; smARF, a short, mitochondrial
isoform of the ARF tumor-suppressor, induces autophagy
and cell death that is blocked by Beclin 1 or Atg5 RNAi
[109]; the cellular redox state also effects autophagy as
reactive oxygen species regulate the activity of Atg4
through oxidation and thus induce autophagy [110]. Tran-
scriptional positive regulation of autophagy by an accepted
apoptotic regulator was also described. The E2F1 tran-
scription factor was shown to induce autophagy by
upregulating the expression of four different autophagy
genes LC3, Atg1, Atg5, and DRAM [111]. In conclusion, it
is now established that various acknowledged stimulators
of cell death entail the autophagic machinery.
Another layer of complexity stems from the finding that
there exists a cross talk between autophagy and apoptosis.
Moreover, this cross talk varies from positive to
negative feedbacks in different scenarios. Under some
circumstances, autophagy contributes to apoptosis and
consequently augments caspase-dependent cell death. For
example, Atg5 was shown to play a crucial role in IFN-c-
induced cell death by interacting with FADD [112]. Addi-
tionally, activation of autophagy by TNFa in Erwing
sarcoma cells, in which NF-jB (which activates mTOR)
was blocked, was required for induction of apoptosis and
cell death [113]. On the other hand, under certain settings
autophagy is activated only when apoptosis is blocked,
indicative of a negative feedback between the two pro-
cesses. A switch to autophagy when apoptosis is inactivated
could presumably provide a cellular back-up mechanism for
inducing cell death. For example, such a negative feedback
was observed under caspase-8 inhibition which induced
autophagic cell death that was dependent on activation of
the receptor-interacting protein (a serine-threonine kinase)
and JNK [114]. In a different case, treatment with etopo-
side, thapsigargin (inducer of ER-stress), or staurosporine
induced autophagy and cell death in Bax/Bak double knock-
out fibroblasts which are apoptosis-deficient. Notably, cell
death was inhibited when autophagy was blocked either by
Atg5 knock-down, Beclin 1 knock-out, or pharmacological
inhibition of PI3 K activity with 3-MA, indicating that
autophagy was required for cell death in these cells [115].
Likewise, lipopolysaccharides (LPS) triggered macrophage
cell death in the presence of the caspase inhibitor zVAD,
which showed features of autophagy and was inhibited by
Beclin 1 RNAi and chemical inhibitors of autophagy [116].
Caspase inhibition was also shown to trigger autophagy-
mediated selective degradation of the ROS scavenger cat-
alase, leading to accumulation of reactive oxygen species
and cell death, which was inhibited by Atg7 or Atg8 knock-
down [117].
In vivo documentation of autophagic cell death
Notably, although autophagic cell death was demonstrated
mostly in studies performed in cell lines, a physiological
role for the importance of this program of cell death has
been demonstrated as well. In drosophila, autophagic cell
death is essential during the development of the salivary
gland [57]. Massive cell death induced by autophagy is also
associated with progression of neurodegenerative diseases
such as Alzheimer, Parkinson, and others [118–121].
Autophagy in tumor development
Of importance is the understanding of the circumstances
under which autophagy promotes either cell death or cell
survival in the context of tumorigenesis, as this may have
implications in cancer therapy. For the most part,
Fig. 2 The paradox of autophagy. A scheme representing the
different links between autophagy and tumorigenesis. Autophagy
can act either as a tumor-promoting or tumor-suppressing mechanism.
Induction of autophagy by oncogenes and under metabolic stress
serves to fulfill the cell’s energy requirement and hence maintain
viability and induce tumor formation. On the other hand, autophagy
suppresses tumorigenesis by blocking angiogenesis and necrotic
inflammation, which promote tumor growth. Autophagy is also
important for tumor-suppression through immuno-surveillance by
mediating tumor antigen presentation. Finally, sustained autophagy
leads to cell death
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autophagy has been shown to suppress tumor growth.
Accordingly, and as previously discussed, various tumor-
suppressors (e.g., PTEN, TSC1-TSC2, p53, and DAPk) are
inducers of autophagy, while some inhibitors of autophagy
(e.g., Akt, Ras) possess oncogenic activity. In contrast,
there is also evidence that autophagy can positively con-
tribute to tumor-progression. This discrepancy might be
explained by the dual-functionality of autophagy, which
depends on both the cellular and extra-cellular settings, as
will be discussed below. Thus, deciphering this controversy
demands the investigation of autophagy in each cellular
scenario individually.
During tumor development, transformed cells undergo a
sequence of events that include intra-cellular alterations as
well as changes in their microenvironment. These changes
seem to be the decisive factors in the autophagy-induced
cell fate. One of the first stages in tumorigenesis is onco-
genic transformation, which often corresponds to aberrant
growth factor signaling and constitutive PI3K/AKT/mTOR
activation. Such conditions, in which protein synthesis and
proliferation are enhanced, create an increased energy
demand in the cell. However, as autophagy, which is the
main alternative source for energy, is blocked by the
constitutive activation of mTOR, transformed cells often
reach the state of metabolic catastrophe. Additionally, as
the transformed cells grow and form a solid tumor, nutri-
ents become unavailable to cells inside the tumor mass that
then become metabolically stressed. Only in later stages of
tumor-progression angiogenesis is completed and sufficient
blood supply reaches the tumor cells. Interestingly, it was
shown that the metabolically stressed regions of the tumor
mass, but not the vascularized ones, activate the autophagic
machinery [122, 123]. Similarly, 3D morphogenesis assays
of mammary epithelial cells showed that autophagy is
activated only in the central acinar cells, which are under
increased metabolic stress [123]. Therefore, autophagy is
induced in transformed cells undergoing metabolic stress, a
feature commonly associated with human solid tumors
[124]. Activation of autophagy might confer a growth
advantage to these cells through the restoration of energy
levels, in agreement with a role for autophagy in promoting
tumor survival.
In contrast to its suggested role in promoting the sur-
vival of metabolically stressed tumor cells, autophagy has
also been widely implicated in suppression of tumorigen-
esis. In apoptosis-deficient cells, inactivation of the
autophagic machinery, coincidently with metabolic stress,
results in the induction of necrotic cell death [122]. During
necrosis, cells release pro-inflammatory factors such as the
high mobility group B1 (HMGB1) protein to the extra-
cellular milieu. These factors recruit macrophages, which
produce cytokines and chemokines that impact prolifera-
tion and angiogenesis at the site of the inflammatory
infiltrate. For simplification, this could be analogous to the
process of wound healing, where inflammatory factors
induce cell proliferation. Thus, the initiation of an
inflammatory response to stress-mediated tumor necrosis
may act to stimulate angiogenesis and promote tumor
growth. Such a phenomenon was demonstrated in apopto-
sis-deficient cells where inactivation of autophagy-induced
necrosis that stimulated an inflammatory response and was
associated with tumor growth [122]. Thus, in the case of
apoptosis-deficient cells, induction of autophagy during
metabolic stress suppresses necrosis and acts as a tumor-
suppressive mechanism. It should be noted, however, that
stimulation of an immunogenic response can also help
remove stressed cells, and cancer cells often evade this step
leading to their uncontrolled proliferation. Antigen pre-
sentation by tumor cells enables the immune system to
recognize and eliminate primary tumors in a process
known as immunosurveillance [125]. The first connection
between autophagy and the immune system came from
reports showing that autophagy can be regulated by dif-
ferent immune factors such as IFN-c, which positively
regulates autophagy [101, 126] and IL-13, which inhibits
autophagy through class I PI3K [127]. Autophagy was also
shown to promote MHC class II presentation of peptides
[128]. Additionally, recent findings suggest a role of
autophagy in tumor antigen presentation and autophago-
somes were suggested to act as antigen carriers for cross-
presentation in vitro. Moreover, it was demonstrated in
melanoma tumor cells that autophagy is essential for cross-
presentation in vivo [129]. The involvement of autophagy
in the acquisition of adaptive immunity against tumors
could present new approaches in development of anti-
cancer vaccines.
An additional characteristic of autophagy in tumor-
suppression is the maintenance of genome integrity. Under
metabolic stress, impairment of the autophagic machinery
resulted in genomic instability that included DNA double-
strand breaks, centrosome abnormalities, and increased
DNA content [130]. Gene amplification is the major
mechanism of oncogene activation in cellular transforma-
tion. Enhanced chromosomal instability and gene
amplification was observed in Beclin 1 heterozygote cells
overexpressing Bcl-2 [130]. The increased gene amplifi-
cation and mutation rates enables these cells to overcome
the loss of autophagy-mediated survival under metabolic
stress. Similar findings were also demonstrated in vivo
where autophagy was induced in metabolically-stressed
regions of mice tumors. Allelic loss of Beclin 1 resulted in
enhanced genomic damage in these mice [123]. Genome
integrity might be maintained via autophagy-mediated
elimination of damaged organelles and proteins. Depolar-
ized mitochondria are a source for genotoxic free radicals.
In the absence of autophagy as a scavenger mechanism,
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DNA mutations accumulate readily and may lead to cel-
lular transformation. Of note, the susceptibility of
autophagy-compromised cancer cells to DNA-damage in
response to metabolic stress might be of therapeutic sig-
nificance. Pharmacologic depletion of pyrimidines with the
chemotherapeutic agent PALA, which depletes pyrimidine
nucleotide (dNTP) pools, triggers the onset of autophagy
that is required to limit gene amplification, suggesting that
autophagy-deficient cells may be particularly prone to this
specific metabolic stress [130].
Autophagy also regulates angiogenesis through inhibi-
tion of vascular endothelial growth factor (VEGF)
signaling. In response to metabolic stress, the pro-angio-
genic protein neuropilin 1, which binds VEGF in both
endothelial and carcinoma cells, is rapidly degraded by
autophagy [131]. mTOR-inhibitors were also demonstrated
to effectively block angiogenesis in vivo in correlation with
induction of autophagy [132, 133]. Therefore, stimulating
autophagy can inhibit tumor-progression by blocking
angiogenesis. However, under certain circumstances
autophagy may have an opposite effect. Autophagy was
induced by the anti-angiogenic drug kringle 5 in human
endothelial cells. However, blocking autophagy enhanced
the anti-angiogenic activity of kringle 5 by inducing
apoptotic cell death of the endothel [134].
In summary, autophagy possesses both tumor-promoting
and tumor-suppressive properties (Fig. 2). It is the specific
intra- and extra-cellular context that determines in which
cell fate induction of autophagy will culminate. Exploita-
tion of autophagy for anti-cancerous purposes should take
into account such variables including the stage in tumori-
genesis, the integrity of the apoptotic machinery in the
tumor, and the consequences of a necrotic inflammatory
response. Some examples of how autophagy is manipulated
in cancer therapy are discussed in the following section.
Autophagy-inducing drugs in cancer therapy
An emerging difficulty in the treatment of cancer patients is
the development of tumor resistance to radiation and drug
therapy. In particular, various malignant cells acquire
mutations and/or deletions in genes that are crucial for the
induction of apoptosis, thus rendering them incapable of
executing apoptotic cell death. Such tumors display resis-
tance to apoptosis-inducing drugs and are challenging to
treat. Unfortunately, these tumors also often correlate with
poor prognosis. The increasing amount of data that have
accumulated in the last years signifying autophagy as a
mechanism of programmed cell death presents new
opportunities for developing alternative anti-cancer thera-
pies. Accordingly, activation of autophagy in apoptosis-
resistant tumors, possibly in combination with inhibitors of
necrosis, could provide a way to induce cell death and
impede tumor growth. Indeed, several autophagy-inducing
drugs are already being used in the clinic for the treatment
of different malignancies and numerous other compounds
are now in clinical trials. The following section describes
some of the interesting examples of autophagy-inducing
drugs in the treatment of malignancy.
Arsenic trioxide (As2O3)
Prevalently used in the clinic for the treatment of hema-
tological malignancies, arsenic trioxide is a powerful
therapeutic tool that induces high rates of complete
remission with no reported severe side effects [135]. The
cytotoxic effects of arsenic trioxide have been attributed to
the induction of apoptosis following cytochrome c release
and caspase activation. However, recently, treatment of
human T-lymphocytic leukemia cells with arsenic trioxide
was shown to cause cytotoxicity through induction of
autophagy as well [136]. A remarkable feature of arsenic
trioxide is its success in the treatment of malignant glioma
cells, which in contrast to hematological malignancies
display resistance to many types of therapy including
radiation, chemotherapy and a range of drugs. Interest-
ingly, arsenic trioxide was shown to be effective in the
growth inhibition and induction of cell death in malignant
glioma cells through activation of autophagy. Treatment
with clinically used low doses of arsenic trioxide (2 lM)
resulted in the formation of autophagic vacuoles and
autophagy was shown to be the cause of cell death in these
cells [137]. The Bcl-2 family member, Bcl-2-adenovirus
E1B 19-kDa-interacting protein 3 (BNIP3), plays a major
role in arsenic trioxide-induce autophagic cell death in
malignant glioma cells. BNIP3 expression is upregulated
following arsenic trioxide treatment and it is required for
the induction of autophagy and cell death in these settings
[138]. Interestingly, when autophagy was inhibited by
Bafilomycin A1, apoptosis was alternatively induced by
arsenic trioxide [137], suggestive of a complex cross-reg-
ulation of the apoptotic and autophagic networks. In
conclusion, induction of autophagic cell death by arsenic
trioxide provides promising new opportunities for the
treatment of resistant malignant gliomas and is now in
clinical trials.
Imatinib (Gleevac)
The competitive Bcr-Abl tyrosine kinase inhibitor imatinib
is widely used for the treatment of chronic myelogenous
leukemia (CML) as well as other malignancies. Recent
data suggest that imatinib induces autophagy in human cell
lines as part of its mode of action [139]. Administration of
imatinib to multi-drug-resistant Kaposi’s sarcoma cells
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also resulted in the induction of autophagy and reduced
survival of these drug resistant cells [140]. In rat C6
chemo-resistant glioma cells, combinatorial treatment of
imatinib with Anafranil, an anti-depressant shown to have
anti-neoplastic activity, significantly induced apoptosis and
autophagy in a synergistic effect and resulted in growth
inhibition and cell death [141]. Additionally, imatinib was
found to be effective in the treatment of glioblastomas in
several clinical trials.
Histone deacetylase inhibitor (HDAC) suberoylanilide
hydroxamic acid (SAHA)
HDAC inhibitors, such as SAHA, demonstrate an anti-
proliferative function and lead to growth arrest and cell
death in various transformed cells both in vitro and in vivo.
Through the regulation of histone acetylation, HDAC’s
influence multiple targets and have an effect on cell fate.
SAHA treatment, currently in clinical trials, proves to be
effective in the treatment of both hematologic and solid
tumors [142]. Evidence shows that SAHA-induced cell
death in Hela cells is caused by the induction of autophagy
and is independent of caspase activation and apoptosis
[143]. In addition, SAHA treatment successfully inhibited
growth of chondrosarcoma cells that show high resistance
to conventional therapy and is usually efficiently treated
only by surgical procedures [144]. Activation of autophagy
by SAHA in these cells was shown to induce cell death and
remarkably resulted in inhibition of tumor growth in mice
xenograft models [144]. Thus, initiation of autophagic cell
death by SAHA has clear therapeutic implications for
apoptosis-defective tumors.
SAHA treatment has also been shown to be effective in
the treatment of imatinib-resistant primary cells from CML
patients bearing mutations in Bcr-Abl that correlate with a
poor clinical prognosis [145]. However, contrary to the
aforementioned, in this case the anticancer activity of
SAHA was enhanced when autophagy was blocked with 3-
MA and chloroquine. Importantly, p53 is not required for
the induction of cell death and therefore this combinatorial
treatment could be a promising for the treatment of
refractory CML with p53 alterations [145].
EB1089 (vitamin D3 analog)
The vitamin D3 analog EB1089 is effective in the growth
arrest and induction of cell death in various malignant cells
[146]. Cell death following EB1089 administration in
breast cancer cells is associated with autophagy. The
monoallelic deletion of Beclin 1 in these cells confers
partial resistance to EB1089 and restoration of Beclin 1
expression to normal levels sensitizes to EB1089 and
reduces tumor growth [147]. EB1089 also potentiated the
response of breast cancer cells to irradiation and led to the
induction of autophagic cell death [148]. Vitamin D3
analogs are now in clinical trials for the treatment of var-
ious malignancies.
mTOR-inhibitors
Rapamycin, a macrolide antibiotic produced by Strepto-
myces hygroscopicus, was initially approved by the Food
and Drug Administration as an immunosuppressant in
1999. Rapamycin binds the 12 kDa immunophilin FK506-
binding protein (FKBP12) and inhibits the mTORC1
complex. As mTOR is a major regulator of cell growth that
has been implicated in tumorigenesis, rapamycin treatment
has anti-cancerous properties and is now in advanced
clinical trials for the treatment of various malignancies.
Rapamycin derivatives, CCI-779 and RAD001, also dem-
onstrate promising results in advanced clinical trials and
hold the advantage of showing no immunosuppressive
effects at intermittent dosing. The anti-cancer properties of
rapamycin were initially attributed to the downregulation
of AKT signaling. Nonetheless, a growing collection of
evidence suggests that tumor-suppression following rapa-
mycin administration is associated with the induction of
autophagic cell death.
Here are some examples linking efficient anti-cancer
intervention by mTOR-inhibitors to autophagy. mTOR-
inhibitors sensitize various tumor cells to radiation therapy.
Combined treatment of RAD001 with the caspase-3
inhibitor DEVD radiosensitized non-small cell lung cancer
cells in mice models and resulted in enhanced cytotoxicity
and delayed tumor growth. The increased cytotoxicity was
linked to the induction of autophagy [133]. Autophagy was
required for susceptibility to cell death in irradiated breast
and prostate cancer cells after rapamycin and RAD001
treatment, respectively [149, 150]. Treatment of mantle
cell lymphoma with CCI-779 and RAD001 induced tumor
remission with a 30–40% response rate [151–153]. Like-
wise, the efficacy of rapamycin and its analogs in inhibiting
cell growth and inducing cell death was demonstrated in
mantle cell lymphoma cell lines and primary tumor cells
[154]. These studies demonstrated an apoptosis-indepen-
dent cell death mechanism in response to mTOR-inhibition
and induction of autophagy was demonstrated in CCI-779-
treated cells [155]. Efficient cytotoxicity caused by mTOR-
inhibitors was also demonstrated in malignant gliomas and
correlated with induction of autophagy [156, 157]. Inter-
estingly, inhibiting mTOR activity with these agents has
also been shown to effect tumor vasculature. Block of
angiogenesis and enhanced radiosensitization was observed
in malignant glioma cells treated with rapamycin and
RAD001 [132], and in apoptosis-inhibited lung cancer cells
as well as lung cancer xenograft model with the
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combination of Z-DEVD and RAD001 [133]. Thus,
mTOR-inhibitors could be used as anti-angiogenic drugs
when combined with radiation.
In conclusion, inhibition of mTOR by rapamycin or its
derivatives provides a powerful therapeutic tool for the
treatment of various malignancies. The recognition that
autophagy has a prominent role in the cytotoxic effects of
these compounds is therapeutically beneficial and could
lead to the development of new combinatorial treatments
whereby autophagy will be specifically induced to fight
tumorigenesis.
Conclusions and perspectives
Exploitation of autophagy for cancer treatment presents
novel therapeutic opportunities. However, the multifaceted
nature of autophagy and its diverse cross talk with other
programs of cell death must be concerned when targeting
the autophagic system. As the outcome of inducing
autophagy varies from conferring a growth advantage up to
promoting cell death, and as the function of autophagy is
determined by the complete genetic makeup of every cell
as well as by the environmental cues a cell is exposed to,
no simple rule can be drawn as to the outcome of targeting
autophagy. Thus, identification of a ‘‘fingerprint’’, which
includes these parameters, for every cancer type is essential
for selecting an effective treatment. Moreover, with various
autophagy-inducing drugs, such as those discussed above,
already in clinical use, the main challenge today is to
determine when to apply each drug, depending on the
biological understanding of the status of the cancer cells.
Importantly, precaution must be taken in application of
these drugs as they may have multiple effects other than
autophagy. In the last years the field of autophagy has
expanded greatly and with it our understanding of this
intricate process. Still, further studies, which will investi-
gate the manipulation of autophagy in vivo, specifically in
mammals, are necessary for projecting the available
knowledge onto the clinic. As key findings continuously
arise, it is anticipated that autophagy will be increasingly
employed in fighting tumorigenesis.
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